CJC-1295 no DAC + Ipamorelin Blend | 99.97% Purity

99.97% Purity Avg. mass 11.40 mg

Each vial contains 5 mg CJC-1295 (no DAC) + 5 mg Ipamorelin in lyophilized form.

CJC-1295 (no DAC), also known as Modified GRF 1–29, is a synthetic analog of growth hormone–releasing hormone (GHRH) with a short biological half-life of approximately 30 minutes. It stimulates the anterior pituitary to secrete growth hormone in discrete pulses — preserving the physiological pulsatility of the GH axis rather than producing sustained, supraphysiological elevation. This distinction is critical: unlike the DAC-conjugated variant, the no-DAC form avoids prolonged receptor stimulation and the associated risk of GH receptor desensitization observed in preclinical models.

Ipamorelin is a highly selective growth hormone secretagogue (GHS) that acts through the ghrelin receptor (GHSR-1a) to trigger pituitary GH release through a pathway independent of GHRH signaling. Notably, ipamorelin does not stimulate significant increases in cortisol, prolactin, or ACTH at effective doses — making it one of the cleanest GHS compounds available for controlled research.

Rationale for the combination:

When administered together, CJC-1295 (no DAC) and ipamorelin activate two complementary arms of the GH secretory axis — GHRH receptor–mediated release and ghrelin receptor–mediated amplification. Published data indicate this dual-pathway activation produces a GH response significantly greater than either peptide alone, while maintaining a pulsatile release profile that closely mirrors endogenous GH secretion patterns. In preclinical research, elevated pulsatile GH has been associated with increased IGF-1 expression, enhanced lipolysis, improved nitrogen retention in skeletal muscle, and upregulated tissue repair signaling — particularly during sleep-phase secretory windows.